Inovio Pharmaceuticals Inc., of Blue Bell, Pa., began a Phase II trial of VGX-3100, a DNA vaccine for cervical dysplasia and cancer caused by human papilloma virus. The randomized, placebo-controlled, double-blinded study will include 148 adult females with cervical intraepithelial neoplasias who have HPV type 16 or 18 confirmed by biopsy.